US FDA Reopens Door For CBD Safety Data, But NPA Says Window Closing For Setting Safe Level
As it recently told Congress it would, FDA reopens docket on “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived,. "Reopening the comment period will do nothing to protect public health when the FDA is already sitting on a ticking time bomb," says NPA head Daniel Fabricant.
You may also be interested in...
The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.
Four major trade organizations applauded the introduction of HR 8179, which would remove statutory impediments to CBD’s lawful use in dietary supplements, subjecting CBD to the same requirements in place for any new dietary ingredient. The Natural Products Association, on the other hand, is calling the bill a misstep.
Living Senior claimed its CBD tinctures, oral strips and capsules could help prevent or treat COVID-19. It featured on its website recommendations by Bob Melamede, a cannabinoids, cancer, and DNA repair professor at the University of Colorado, and Richard Cowan, formerly executive director of NORML.